Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-062-1 | CAS number: 115-07-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
A useful understanding of the toxicokinetics in rats, mice and humans has emerged.
Uptake of propene in the lung is controlled by the blood:air partition coefficient, the perfusion rate of the lungs and at high concentrations by saturable metabolism. At concentrations of propene that do not result in saturation of metabolism, about 90% of inhaled propene was exhaled unchanged; this is due to the low uptake from the alveoli into blood.
Metabolism of propene to propene oxide is saturable. Blood concentrations of propene oxide at steady state are low and not expected to increase substantially above the value reached at 3000 ppm (5,200 mg/m3).
Volunteer studies indicate that a similar situation, at least in part, exists in humans.
Exposure of both rats and humans to propene concentrations of approximately 25 ppm (43 mg/m3) results in similar concentrations of propene in blood however concentrations of propene oxide in human blood were approximately 60-fold lower than in rat blood.
PBPK modelling indicates that following exposure as described above, 35% of inhaled propene enters the blood and 20% of this is metabolised; this indicates that 7% of inhaled propene is metabolised, the remainder is exhaled unchanged.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - inhalation (%):
- 35
Additional information
Non-human information
Absorption
In mice, the rate of uptake of propene by inhalation was saturable exhibiting Michaelis-Menten kinetics. The maximum rate of uptake was 8±0.5 mg propene/kg bwt/h (Svensson and Osterman-Golkar, 1984). In Fischer 344 rats exposed by inhalation to 600 ppm (1,000 mg/m3) propene, blood concentrations of propene oxide were 740 ng/g within 5 minutes of the start of exposure; corresponding values during exposure to 6 ppm (10 mg/m3) propene were 160 ng/g after 5-12 minutes (Maples and Dahl, 1991). At exposure concentrations that do not saturate metabolism, uptake of propene by inhalation is controlled by the air concentration, the blood:air partition coefficient and the perfusion rate of the lung (Filser et al., 2000).
Distribution
Svensson et al., 1991 found that the levels of DNA adducts in liver, testes, lung, spleen and kidney were similar indicating an even dose distribution in the tissues studied. Following ip administration of propene oxide, liver had a somewhat higher dose than other tissues. Tissue:air partition coefficients for propene measured in-vitro indicate a very low potential for accumulation in tissues; values for adipose were approximately 10x other tissues (Filser et al., 2000).
Metabolism and adduct formation
Two diastereomers of N-(2-hydroxypropyl) histidine were identified in the hydrolysate of haemoglobin from mice exposed by inhalation to propene (20,000 ppm) (34,400 mg/m3) showing that propene is metabolised to the epoxide and that the oxidation is not stereospecific. The amounts of alkylated products in DNA were below the detection limit (Svensson and Osterman-Golkar, 1984). The levels of adducts to N-terminal valine following exposure to propene oxide showed that the dose of propene oxide in blood was linearly related to the administered dose. The levels of adducts in propene-treated mice show that propene oxide is a major metabolite of propene (Svensson et al., 1991). The maximum rates of metabolism (Vmax) of propene were 110 and 50.4 µmol/h/kg for mouse and rat respectively; Vmax/2 was reached at 270 ppm and 400 ppm (460 and 690 mg/m3) in mice and rats respectively (Filser et al., 2000). Cytochrome P450 activity in both the liver and the nasal microsomes of rats were initially reduced during exposure to propene but had returned to approximately their initial values within 6h (Maples and Dahl, 1991). In Fischer 344 rats exposed to propene, concentrations of exhaled propene oxide decreased during exposure suggesting rapid inactivation of propene oxide producing cytochrome species. The saturation kinetics of the metabolism of propene is reflected by the propene oxide concentrations in blood (Filser et al., 2008) . In male and female rats exposed to propene by inhalation, the presence of HPVal adducts in systemic blood and N7-HPGua adducts in tissue from all treated groups demonstrated internal exposure to propene oxide. The number of adducts increased with exposure concentration up to 2,000 ppm (3,440 mg/m3) reaching a plateau above this concentration; this is likely to be due to saturation of the P450 mediated formation of propene oxide. The number of N7-HPGua adducts was similar in all tissues examined (Pottenger et al., 2007).
Elimination
Exhalation is the major route of elimination of propene. During exposure by inhalation to concentrations of propene that do not result in saturation of metabolism, 92% and 86% of inhaled propene was exhaled unchanged in rat and mouse respectively; this is due to the low uptake from the alveoli into blood (Filser et al., 2000).
Human Information
Following exposure of a healthy male volunteer to propene by inhalation, propene concentrations in exhaled air dropped rapidly. A physiological toxicokinetic model predicted that propene is eliminated so rapidly in humans that it cannot accumulate and that 35% of inhaled propene enters the blood, 20% of this is metabolised indicating that 7% of inhaled propene is metabolised, the remainder is exhaled unchanged (Filser et al., 2000)
In four male human volunteers exposed by inhalation to propene for 3 hours, the mean rate of metabolism was 30 µmol/h at an exposure concentration of 25 ppm (43 mg/m3); the majority of inhaled propene being exhaled unchanged. Mean blood concentrations of propene oxide calculated assuming a blood:air partition coefficient of 66 were 0.44 and 0.92 nmol/L at mean propene exposure concentrations of 9.82 and 23.4 ppm (17 and 40 mg/m3), respectively (Filser et al., 2008)
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.